| Date Filed | Type | Description |
| 03/28/2013 |
10-K
| Annual Report for the period ended December 31, 2012 |
| 03/28/2013 |
8-K
| Quarterly results |
| 03/19/2013 |
8-K
| Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arran... |
| 01/11/2013 |
15-12G
| Form 15-12G - Securities registration termination [Section 12(g)] |
| 01/11/2013 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
| 11/14/2012 |
8-K
| Quarterly results|
Docs:
|
"ANGIOTECH ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2012 Vancouver, BC, November 14, 2012 — Angiotech Pharmaceuticals, Inc. announced that it released its financial results for the third quarter ended September 30, 2012. Angiotech will host a conference call discussing its first quarter financial results on November 15, 2012 at 1:00 PM ET . Details regarding the conference call can be found on Angiotech's website at www.angiotech.com. “Our business performance in the third quarter continued to reflect exceptional efforts by our staff to turn our business around in 2012 and move it forward on a renewed path,” said Thomas Bailey, President and CEO of Angiotech. “Consistent with the first half of the year, we were able to continue our revenue growth, and our gross ..." |
|
| 11/14/2012 |
10-Q
| Quarterly Report for the period ended September 30, 2012 |
| 11/13/2012 |
10-Q/A
| Quarterly Report for the period ended June 30, 2012 [amend] |
| 09/20/2012 |
8-K
| Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arran... |
| 09/13/2012 |
10-Q/A
| Quarterly Report for the period ended June 30, 2012 [amend] |
| 08/16/2012 |
8-K
| Credit agreement amendment|
Docs:
|
"Indenture, by and among Angiotech Pharmaceuticals (US), Inc., Angiotech Pharmaceuticals, Inc., certain of its subsidiaries party thereto and Deutsche Bank National Trust Company, as trustee, for 9% Senior Notes due 2016",
"Supplemental Indenture, by and among Angiotech Pharmaceuticals, Inc., certain of its subsidiaries party thereto and Deutsche Bank National Trust Company, as trustee, for Senior Floating Rate Notes due 2013",
"Press Release" |
|
| 08/14/2012 |
10-Q
| Quarterly Report for the period ended June 30, 2012 |
| 08/14/2012 |
8-K
| Quarterly results|
Docs:
|
"ANGIOTECH ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2012 Vancouver, BC, — Angiotech Pharmaceuticals, Inc. announced that it released its financial results for the second quarter ended June 30, 2012. Angiotech will host a conference call discussing its first quarter financial results on August 15, 2012 at 1:00 PM ET . Details regarding the conference call can be found on Angiotech's website at www.angiotech.com. “We are extremely pleased to announce our third consecutive quarter of significantly improved financial results. Our improved revenue growth, cash flows, liquidity and profitability are a culmination of the hard work and dedication of our team following the conclusion of our restructuring and business change initiatives last year,” said Thomas Bailey, Angiote..." |
|
| 06/26/2012 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 06/25/2012 |
4
| Highland Crusader Offshore Partners, L.P. (10% Owner) has filed a Form 4 on ANGIOTECH PHARMACEUTICALS INC|
Txns:
| Sold 1,115,000 shares
@ $15.43, valued at
$17.2M
|
|
| 06/14/2012 |
3
| Highland Crusader Offshore Partners, L.P. (10% Owner) has filed a Form 3 on ANGIOTECH PHARMACEUTICALS INC |
| 06/14/2012 |
SC 13G
| HIGHLAND CAPITAL MANAGEMENT LP reports a 12.3% stake in Angiotech Pharmaceuticals, Inc. |
| 05/15/2012 |
10-Q
| Quarterly Report for the period ended March 31, 2012 |
| 05/15/2012 |
8-K
| Form 8-K - Current report |
| 04/10/2012 |
8-K
| Form 8-K - Current report |
| 03/29/2012 |
10-K
| Annual Report for the period ended December 31, 2011 |
| 03/16/2012 |
8-K
| Form 8-K - Current report |
| 11/09/2011 |
10-Q
| Quarterly Report for the period ended September 30, 2011 |
| 11/09/2011 |
8-K
| Form 8-K - Current report |
| 10/21/2011 |
8-K
| Form 8-K - Current report |
| 08/17/2011 |
10-Q/A
| Quarterly Report for the period ended June 30, 2011 [amend] |
| 08/09/2011 |
8-K
| Quarterly results |
| 08/09/2011 |
10-Q
| Quarterly Report for the period ended June 30, 2011 |
| 07/20/2011 |
8-K
| Form 8-K - Current report |
| 07/15/2011 |
8-K
| Termination of a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointmen... |
| 06/06/2011 |
EFFECT
| Form EFFECT - Notice of Effectiveness |
| 06/02/2011 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement |
| 05/17/2011 |
4/A
| Neske Tammy (SVP, Human Resources) has filed a Form 4 on ANGIOTECH PHARMACEUTICALS INC|
Txns:
| Disposed of 3,000 shares
@ $0
Disposed of 3,300 shares
@ $0
Disposed of 5,500 shares
@ $0
Disposed of 85,000 options to buy
@ $0
Disposed of 150,000 options to buy
@ $0
Disposed of 50,000 options to buy
@ $0 |
|
| 05/17/2011 |
4/A
| Gross Jeffrey M (SVP, Research & Development) has filed a Form 4 on ANGIOTECH PHARMACEUTICALS INC|
Txns:
| Disposed of 9,000 shares
@ $0
Disposed of 6,000 shares
@ $0
Disposed of 1,500 shares
@ $0
Disposed of 2,000 shares
@ $0
Disposed of 20,000 shares
@ $0
Disposed of 12,500 shares
@ $0
Disposed of 85,000 options to buy
@ $0
Disposed of 150,000 options to buy
@ $0
Disposed of 100,000 options to buy
@ $0
Disposed of 25,000 options to buy
@ $0 |
|
|